RecruitingNCT06728709

Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients

Lung Assessment and Monitoring in Critically Ill Obstetrics and Gynecological Patients by Point of Care Ultrasound; Prospective Observational Study


Sponsor

Ain Shams University

Enrollment

64 participants

Start Date

Dec 15, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population


Eligibility

Sex: FEMALE

Inclusion Criteria1

  • Any patient admitted to the obstetrics and gynecology intensive care unit

Exclusion Criteria2

  • Patient's refusal
  • inability to do a lung ultrasound examination during the first 24 hours of admission

Interventions

DIAGNOSTIC_TESTultrasound detection of any abnormal ultrasonographical findings.

ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress. While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 8-region technique will be used. The areas are four on each side of the chest. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left . Each region will be scored using the LUS aeration score. as follows: "0," A-pattern with 0-2 B-lines; "1," more than 2 separated B-lines; "2," multiple coalescent B-lines; or "3," lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 24. posterior region will be assessed if needed and if feasible. The venous status will be assessed through a subcostal view for inferior vena cava diameter.


Locations(1)

Ain shams university

Cairo, Cairo Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06728709


Related Trials